NCT01148966 arm group 3a659de2ceec31e4913016d94e8b89ac [clinicaltrials_resource:NCT01148966/arm-group/3a659de2ceec31e4913016d94e8b89ac]
laboratory biomarker analysis [clinicaltrials_resource:39d4b844d544bb37839ffa36b00b5347]therapeutic conventional surgery [clinicaltrials_resource:e5979b42d039869be707c17e08742908]aminolevulinic acid [clinicaltrials_resource:e5bfba5d3bce5bb43d15879ba752dcd5]Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors [clinicaltrials:NCT01148966]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01148966 arm group 3a659de2ceec31e4913016d94e8b89ac [clinicaltrials_resource:NCT01148966/arm-group/3a659de2ceec31e4913016d94e8b89ac]
Bio2RDF identifier
NCT01148966/arm-group/3a659de2ceec31e4913016d94e8b89ac
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 659de2ceec31e4913016d94e8b89ac
description [clinicaltrials_vocabulary:description]
Patients receive aminolevulinic acid PO 4 hours before undergoing surgery.
identifier
clinicaltrials_resource:NCT01148966/arm-group/3a659de2ceec31e4913016d94e8b89ac
title
NCT01148966 arm group 3a659de2ceec31e4913016d94e8b89ac
@en
type
label
NCT01148966 arm group 3a659de2 ...... 59de2ceec31e4913016d94e8b89ac]
@en